Our vape products only contain high quality cannabis distillate and natural terpenes.
We do not use any harmful additives or diluents in our products such as:
PG
VG
MCT
Vitamin E Acetate
At MedPharm we put the consumer first.
Colorado’s First Licensed
Cannabis Research Facility
COMBINING CANNABIS AND SCIENCE
VISION
MedPharm is a phytopharmaceutical and intellectual property holding company that has been created to develop innovative cannabis products, using accepted pharmaceutical formulation techniques, to reliably produce identifiable and replicable dosage forms for human use.
MISSION
MedPharm will lead the industry in developing products to improve the human condition and better the lives of those who suffer from disease. It is MedPharm’s intent to position itself to have safe, reliable, proven products ready for Phase I formulations when such trials become available.
OBJECTIVE
Scale and implement a state-based production laboratory model to test, create and produce pharmaceutical-type cannabis, using intellectual property or proprietary formulations and methods for a variety of dosage forms.
OPERATION MODEL/SCIENCE METHODOLOGY
To provide cannabis pharmaceutical-type products using current Good Manufacturing Practices (cGMP) that would include pre-formulation, formulation development, small scale commercial manufacturing, analytical method development and validation, routine quality control analysis, and stability studies.
To create pharmaceutical dosage forms and produce ingredients utilizing pharmaceutical technology to be used in the delivery of cannabis extracts. The goal is to provide a reliable clinical effect through the use of well-crafted and well-researched oil analytics and dosage forms.
MedPharm is not making specific therapeutic claims. The use of the term pharmaceutical, pharmaceutical grade, pharmaceutical dosage forms, etc. are indicative of the process by which new formulation products will be created with the intent of accurately identifying the active ingredients and the amount of each in each dosage form using best practices associated with traditional pharmacy formulations. MedPharm is seeking to take existing anecdotal evidence and through its own formulation process further identify which cannabis varieties and strains are best suited to which disease states.
MedPharm’s founders include a pioneer and leader in cannabis cultivation, a leading pharmacy company, which specializes in formulation development and the world’s leading plant extraction company.
Leveraging our proprietary Lipophilic Enhanced Absorption Formulation (L.E.A.F.™) technology, MedPharm can target specific dosage categories, including oral, transdermal and the possibility sterile in the future.
Includes: grow, extraction, R&D, new formulations, or reformulating into products/brands for creams, suppositories, vaporizers, brands like: become, Batch etc.
Management and Consulting Services
Hands-on training of product creation and operational methodologies. MX, LLC leverages MedPharm Holdings for oversight, product development and employees.
Lease Fees on Property and Equipment
MX, LLC uses MedPharm facility and subleases the property with equipment MedPharm Holdings owns. This makes for a scalable business solution that can be taken to other markets.
Current Licensees
Consulting Services
MedPharm’s team of scientists and experts is uniquely positioned to perform groundbreaking research
in cannabis therapeutics. MedPharm’s team includes chemists, a PhD in medicinal and natural products
chemistry, compounding pharmacist and formulation development expert. MedPharm can create
any dosage form with any desired combination of cannabinoids and, due to the possession of the
only Cannabis Research License granted by the State of Colorado, MedPharm can also administer
placebos out of its main facility. This means that MedPharm can provide study medications, placebos,
and support for Randomized-Controlled Trials (RCTs) and more.
MedPharm Consulting services are available in every state Marijuana is available. With multiple levels of service, we can consult on your entire operation from start (Application) to finish (build and processes). We also offer “pick and choose” consulting for those companies that need only need help with specific steps in the process.
Application Support- In every state with legislation, we have a team of industry experts, political figures, and lawyers that can prepare, review, submit, or co-submit your application.
Facility design- Whether its a fully custom built from scratch plan, or a unique pre-existing building, our team of growers and extract specialist will configure the best set up for your operation. Our team is knowledgeable in each state’s rules and regulations.
Cultivation- We will fully cater to your needs, choosing your options in: Lights, heating and cooling solutions, soil/clay options, food and water preference, cloning, trimming and shucking, flower/veg cycling, controlling and monitoring solutions.
Extraction- Our expertise. Extraction is the process of turning the plant matter into a concentrate. We offer in depth training, as well as a wide variety of choices in extraction methods, and post processing methods for any products you are considering making.
Formulation Development- With wide ranges of Cannabinoids, terpene profiles, and extraction methods comes unique combinations. We can build custom formulations or teach consistent dosing on any formulation your company needs.
Packaging- design, compliance, set up, process, any solutions you need when it comes to packaging any product, we have the solution.
Licensing of MedPharm Brands- our Aliviar, Batch, and Become brands can all be licensed with our help in showing you how to build consistent forms. There are several options, as well as perks of new products being offered before other networks.
Data analysis- At MedPharm we believe the science behind the product is what separates us. We can consult on the computing, machinery, equipment, and strategies themselves; as well as sharing our in-house data and methods.
R&D- While the cannabis market grows every day, new products grow with it. At MedPharm, our approaches allow us to create and improvise new products.
Metric compliance- Each state has its own rules, and policies. We will ensure as you begin or rework your business structure, you are compliant for long term solutions.
Process optimization- We will take a look at your end goal and put the process in place to get you there with best profit margins, and efficiency possible.
MedPharm has consulting services and can be reached at (720) 697-7555
2017-05-24 @ : CannabisBusinessExecutive.com The DEA play
Our Brands
Contact Us
ALBERT GUTIERREZ, MS
CEO
Albert is an operationally focused executive who leverages his strategic vision to increase production. He has a background in program management and portfolio management. Albert is an Agile Certified Practitioner through the Project Management Institute, Certified Scrum Master, Agile Coach and Certified Scrum Product Owner. Albert has been a part of, and helped build, many successful companies to include: ClickFox, The Regis Company, Qualvu, CBDDOSE.com, HealthGrades.com and Medicine Man. He is responsible for successfully managing several multi-million-dollar projects from: Visa, MasterCard, Google, Ernst & Young, Deloitte, Accenture, AT&T, Verizon, John Deere, Bose and many more. Albert holds a B.S. from Metro State University and a graduate degree from Colorado State University Business School.
ANDY WILLIAMS
MANAGING PARTNER
Andy Williams is the President and CEO of Medicine Man in Colorado. He is veteran of the US Army, and served three years as a Cavalry Scout in the 3rd Infantry Division. He went on to earn a Bachelor of Science degree in Industrial Engineering from the University of Southern Colorado in Pueblo, CO.
Andy has worked in a wide range of manufacturing industries as an industrial engineer, and in leadership positions. He is a lifelong entrepreneur. In 2009 the Ogden letter was published stating the Department of Justice would not utilize their resources to prosecute those individuals following state marijuana laws. That was the call to a new opportunity in the marijuana industry for Andy and his brother Pete.
In December of 2009 they launched Medicine Man with the concept of being the Costco of marijuana. Six years later Medicine Man is now a $17 million a year corporation and has branched out to assist start up marijuana companies and grow facilities across the country with their consulting company, Medicine Man Technologies. They are known as industry leaders throughout the United States.
DR. CHRIS NELSON
MANAGING PARTNER
Dr. Chris Nelson is the owner of MedPharm Iowa, and he is also the president and CEO of Kemin Industries, a global ingredient manufacturer that has been dedicated to using applied science to improve the quality of life for over half a century.
As a global company touching 3.8 billion people every day with its products, Kemin is committed to improving the quality, safety and efficacy of food, feed and health related products to feed a growing population and be a resource for others in need. Committed to feed and food safety, Kemin maintains top-of-the-line manufacturing facilities where over 500 specialty ingredients are made for humans and animals in the global feed and food industries, as well as the health, nutrition and beauty markets. The company provides product solutions and options to customers in more than 120 countries.
Dr. Nelson began his career with Kemin in 1980 as director of research and development (R&D). Since 1993, he has served as president and CEO of Kemin. Distinguished among the company’s many commercial and scientific advances is the fact that Kemin pioneered the process of isolating and purifying the antioxidant molecule lutein for human consumption in supplements and fortified foods. Researchers have identified lutein as playing a central role in human eye health, specifically in reducing risk of age-related macular degeneration, the leading cause of adult blindness. Over 60 million people consume lutein daily through multivitamins or concentrated lutein supplements. Under his leadership at Kemin, the company has more than quadrupled in size and now employs nearly 2,500 people.
Dr. Nelson received his undergraduate degree at Northwestern University and his Ph.D. in biochemistry and biophysics from Washington State University. He holds 15 patents and has authored numerous peer reviewed, published research studies.
Dr. Nelson has been named one of the top 100 CEO Leaders in STEM (Science, Technology, Engineering, and Math). He serves on the boards of the Des Moines Symphony and the Des Moines Community Foundation, among others. He continues to have a passion for science education and serves on the Board of the Science Center of Iowa, where he helped lead a successful development effort for construction of the $62 million interactive learning center.
EMMELINE ATTOLINI
...
...
Scott Karolchyk, MS, RPh
Director of Formulation Development
Scott is an accomplished product development leader with extensive experience in pharmaceutical formulation design and development, compounded preparation research, and business management. He is proactive and tenacious in applying knowledge to project initiatives, utilizing communication across divisions to influence and drive project teams with a particular focus on successful delivery of new formulations, clinical trial supplies, regulatory submissions and commercial deliverables.
He received his undergraduate and graduate degrees at the University of Iowa College of Pharmacy in Pharmacy and Pharmaceutical Sciences. He established a state-of-the-art compounding and nutritional pharmacy, Pharmacy Creations, specializing in problem solving and pharmaceutical care with a particular focus on high risk sterile admixtures for the pain management and ophthalmologic markets. He received the New Jersey Innovative Pharmacist Award in 2008 and has several patents including an ophthalmic injection for cataract surgery which currently has 15% of the US market as a compounded medication.
stefanie maletich
Director of Laboratory Operations
Stefanie earned a BS in chemistry with a minor in sociology from Regis University in 2011. She began her career at the National Renewable Energy Laboratory, first as an undergraduate intern and then as a research technician. While at NREL, she performed compositional analysis of biomass in the National Bioenergy Center, specializing in chromatography and spectroscopy techniques. Stefanie participated in notable projects like the 2012 Achievement of Ethanol Cost Targets, which demonstrated advances in cost-competitive cellulosic ethanol production and technology.
In 2015, Stefanie transitioned to the cannabis industry, first as the Supervisory Analyst at Axenico and then as a Chemist at TEQ Analytical Laboratories. She adapted her analytical chemistry experience to the cannabis plant and its products, developing several new methodologies and procedures at both laboratories. Stefanie joined the MedPharm team in late 2017 and is committed to applying her skills on the production and research side of the cannabis industry.
T.J. JOHNSRUD, BSPh
MANAGING PARTNER
TJ Johnsrud, BSPh is founder and president of NuCara Management Group, LLC, headquartered in Conrad, Iowa, which oversees pharmacy locations in Iowa, Illinois, Minnesota, North Dakota and Texas. The NuCara pharmacies are jointly owned by NuCara Management Group and Dakota Drug. In addition to community pharmacy practice, NuCara offers Home Medical Equipment, specialty pharmacy, respiratory services and is an industry leader in sterile and non‐sterile compounding developing patent-ready formulations.
Mr. Johnsrud has been honored for his commitment to excellence in pharmacy in Iowa with the 1991 Bowl of Hygiea, the 2001 Robert G. Gibbs Distinguished Pharmacist Award, the 2003 Distinguished Alumni Award from the University of Iowa College of Pharmacy and the 2014 Osterhaus Medal for Lifetime Achievement.
He has served as Past President and remains a current member of the Iowa Pharmacy Association where he is Chairman of the Task Force on the Iowa Pharmacists New Practice Model. He was the first Chairman of the Board of PACE Alliance multi‐state pharmacy buying group. He is a member of the National Community Pharmacists Association, the American Pharmaceutical Association, the National Association of Chain Drugstores, and a lifetime member of the University of Iowa Alumni Association.
He has served the University of Iowa on the Dean’s Advisory Council for the College of Pharmacy, on the College of Pharmacy Second Century Fundraising Campaign Committee, the University of Iowa College Curriculum Advisory Council and by participating as a President’s Club member since 1983, Golden Hawk member since 1982 and the Kinnick Society since 2003.Mr. Johnsrud was a Liberal A Arts major at Creighton University before graduating with high distinction in 1966 from the University of Iowa with a Bachelor of Science in pharmacy.
TYRELL R. TOWLE, Ph.D.
Director of Chemistry and Extraction
Tyrell received his B.S. in chemistry and minor in mathematics from the University of Washington, Seattle, Washington in 2007. He received his Ph.D. in medicinal and natural products chemistry from The University of Iowa, Iowa City, Iowa in 2013. His thesis research centered around the design, synthesis, and evaluation of fluoroquinolone antibiotics to overcome antibiotic resistant bacteria. He received numerous awards including a 2012 American Chemical Society Medicinal Chemistry Fellowship (sponsored by Richard B. Silverman) and National Institutes of Health T32 Pharmacological Sciences Training Grants. Prior to attending graduate school, Tyrell worked as a chemist in the pulp & paper manufacture, wastewater treatment, and petroleum industries in Bellingham, Washington.
After graduating from the University of Iowa, Tyrell moved back to his home state of Washington to become actively involved in the emerging state-legal cannabis industry. Initially focusing his attention on cannabis extraction methods and safety, he shifted his focus to the analytical chemistry of cannabis while acting as Scientific Director of an I-502 certified quality assurance laboratory in Washington State. Tyrell is passionate about the chemistry and potential therapeutic uses for cannabis and has been a volunteer for the American Chemical Society’s Cannabis Chemistry Subdivision (a subdivision of the Division of Chemical Health and Safety) since 2015.
DUNCAN I. MACKIE, Ph.D.
Director of Pharmacology & Experimental Therapeutics
Duncan is originally from Fort Lauderdale, Florida. In 2006, he earned his Bachelor of Science in Mathematics from The University of the Cumberlands in Williamsburg, Kentucky. He continued his studies in Biology and Chemistry in 2008, while preparing for graduate school.
In 2009, he joined the University of Iowa's Department of Pharmaceutical Sciences and Experimental Therapeutics. As a member of the Division of Medicinal and Natural Products Chemistry, he worked with Dr. David L. Roman. During the course of his graduate studies, Dr. Mackie was named an author on several manuscripts as well as producing two provisional patents for his discovery of the first RGS17 small molecule inhibitors. This work by Dr. Mackie lead to him being named an NIH Pre-doctoral Fellow on the Center of Biocatalysis and Bioprocessing T32 training grant and the American Foundation for Pharmaceutical Education (AFPE) Pre-doctoral Fellowship in Pharmaceutical Science.
Upon graduation in 2014, Dr. Mackie joined the University of North Carolina School of Medicine as a Post-doctoral research associate in the Department of Cellular Biology and Physiology. Dr. Mackie worked closely with Dr. Kathleen Caron applying the principles of medicinal chemistry and pharmacology to understand the complex signaling underlying disease states. During this time, his work was supported through an NRSA grant from the National Heart, Lung, and Blood Institute. The principal focus of his research was the determination of key contributors in the process of angiogenesis. Dr. Mackie’s work focus on G protein coupled receptors (GPCRs) and a family of interacting proteins known as receptor activity modifying protein (RAMPs) and the roles these interactions play in the angiogenic process. These studies may provide novel and unique approaches for the treatment of cardiovascular diseases as well as cancer.
In 2019, Dr. Mackie join MedPharm Holdings as Director of Pharmacology and Experimental Therapeutics. Duncan is currently overseeing the discovery and development of novel therapeutics derived from natural product isolates of the Cannabis and Hemp plants.
Adults Over 21 Only
You must be 21 years of age or older to visit this website.
